Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.1, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $5.92 |
52-Week Low | $17.80 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.11, up 0.22% on the day, with a bearish technical signal driven by moving averages. The ETF shows no available valuation or profitability ratios, and recent news highlights weekly dividend distributions but also concerns over shareholder losses and declining value despite high yields. Technical indicators show RSI near oversold levels at 29.18, suggesting potential for a rebound, while resistance sits at $19.
The outlook remains cautious due to bearish technicals and negative media sentiment questioning sustainability. Risks include reliance on options income and market volatility. Analyst coverage is limited, with no consensus ratings or price targets available, indicating uncertainty for investors.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
